Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Pfizer Inc.'s quarterly P/E stands at 14.4x, up 18.5% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 27.8% YoY to 10.4x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.54 | 14.38 | — | 9.58 | 11.86 | 12.13 | 92.25 | 9.28 | 1665.48 | 12.67 | — | — | 22.49 |
| — | +18.5% | — | +3.3% | -99.3% | -4.2% | — | — | +7304.7% | +20.2% | — | — | +197.3% | |
| P/S Ratio | 2.29 | 2.68 | 2.02 | 2.04 | 2.35 | 2.62 | 2.13 | 2.34 | 3.00 | 2.66 | 2.79 | 3.47 | 4.03 |
| — | +2.1% | -5.3% | -13.0% | -21.5% | -1.2% | -23.7% | -32.5% | -25.5% | -15.9% | -7.9% | +25.6% | +49.6% | |
| P/B Ratio | 1.65 | 1.71 | 1.63 | 1.46 | 1.55 | 1.59 | 1.71 | 1.79 | 1.81 | 1.71 | 1.82 | 1.93 | 2.11 |
| — | +7.9% | -4.6% | -18.7% | -14.4% | -7.0% | -6.1% | -6.9% | -14.2% | -26.0% | -40.7% | -28.5% | -38.2% | |
| P/FCF | 15.81 | 17.77 | 7.86 | 8.48 | — | 20.32 | 6.52 | 6.84 | — | 102.39 | 9.69 | 17.69 | — |
| — | -12.5% | +20.6% | +24.0% | — | -80.2% | -32.7% | -61.3% | — | -87.0% | -0.2% | +45.2% | — | |
| EV / EBITDA | 10.31 | 10.44 | 9.67 | 9.41 | 9.53 | 8.16 | 7.12 | 8.61 | 15.72 | 8.98 | 141.63 | — | 17.35 |
| — | +27.8% | +35.9% | +9.3% | -39.4% | -9.1% | -95.0% | — | -9.4% | +10.2% | +1083.5% | — | +191.5% | |
| EV / EBIT | 13.59 | 13.50 | — | 12.30 | 13.40 | 14.82 | 15.95 | 10.53 | 84.20 | 13.42 | — | — | 24.50 |
| — | -8.9% | — | +16.9% | -84.1% | +10.4% | — | — | +243.6% | +32.7% | — | — | +242.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Pfizer Inc.'s operating margin was 27.9% in Q1 2026, up 6.9 pp QoQ and down 5.8 pp YoY. The trailing four-quarter average of 23.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 6.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.3% | 67.3% | 70.0% | 74.9% | 64.3% | 71.7% | 73.0% | 60.8% | 62.1% | 70.6% | 41.0% | 21.4% | 64.7% |
| — | -6.1% | -4.2% | +23.2% | +3.6% | +1.6% | +77.9% | +184.2% | -4.0% | +4.0% | -25.5% | -69.0% | -3.9% | |
| Operating Margin | 24.7% | 27.9% | 21.0% | 21.3% | 24.4% | 33.7% | 32.2% | 28.1% | 14.1% | 30.6% | -8.7% | -22.3% | 18.1% |
| — | -17.2% | -34.8% | -24.0% | +72.5% | +10.0% | +471.8% | +226.0% | -21.7% | -15.3% | -139.4% | -152.0% | -61.3% | |
| Net Margin | 12.4% | 18.6% | -9.4% | 21.3% | 19.9% | 21.6% | 2.3% | 25.3% | 0.2% | 21.0% | -22.9% | -17.7% | 17.9% |
| — | -14.0% | -513.7% | -15.9% | +10890.3% | +3.2% | +109.9% | +242.4% | -99.0% | -30.1% | -211.6% | -146.5% | -49.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 8.9% | 3.0% | -1.8% | 3.9% | 3.2% | 3.3% | 0.4% | 5.0% | 0.0% | 3.4% | -3.6% | -2.4% | 2.3% |
| — | -8.4% | -511.6% | -21.5% | +12079.3% | -3.5% | +112.4% | +303.4% | -98.9% | -39.0% | -167.8% | -125.5% | -80.0% | |
| ROA | 3.7% | 1.3% | -0.8% | 1.7% | 1.4% | 1.4% | 0.2% | 2.1% | 0.0% | 1.4% | -1.5% | -1.1% | 1.1% |
| — | -8.2% | -524.6% | -16.9% | +12676.4% | +1.0% | +112.3% | +286.6% | -99.0% | -50.6% | -159.5% | -124.9% | -78.5% | |
| ROIC | 7.5% | 2.0% | 1.8% | 1.8% | 1.8% | 2.3% | 2.8% | 2.4% | 0.9% | 2.2% | -0.6% | -1.4% | 1.2% |
| — | -14.1% | -35.0% | -25.9% | +100.7% | +6.9% | +561.7% | +268.4% | -25.2% | -43.3% | -119.3% | -124.4% | -85.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Pfizer Inc.'s Debt/EBITDA ratio is 12.4x — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.78 | 0.71 | 0.78 | 0.66 | 0.69 | 0.68 | 0.72 | 0.72 | 0.78 | 0.74 | 0.79 | 0.65 | 0.66 |
| — | +5.4% | +8.0% | -7.9% | -11.1% | -8.9% | -9.4% | +10.0% | +18.6% | +115.2% | +118.3% | +70.3% | +47.1% | |
| Debt / EBITDA | 3.31 | 12.36 | 12.54 | 11.84 | 11.88 | 9.82 | 8.47 | 9.91 | 19.02 | 10.91 | 174.07 | — | 16.65 |
| — | +25.9% | +48.1% | +19.5% | -37.5% | -10.0% | -95.1% | — | +14.2% | +155.4% | +3329.0% | — | +500.9% | |
| Current Ratio | 1.16 | 1.25 | 1.16 | 1.28 | 1.16 | 1.26 | 1.17 | 1.00 | 0.86 | 1.05 | 0.91 | 2.38 | 2.12 |
| — | -0.9% | -1.0% | +28.2% | +34.2% | +20.1% | +29.2% | -57.9% | -59.2% | -23.5% | -25.5% | +49.6% | +48.8% | |
| Quick Ratio | 0.87 | 0.94 | 0.87 | 0.97 | 0.85 | 0.96 | 0.92 | 0.73 | 0.60 | 0.78 | 0.69 | 2.05 | 1.82 |
| — | -2.5% | -5.1% | +32.9% | +41.1% | +23.4% | +32.5% | -64.4% | -66.9% | -29.8% | -30.9% | +49.1% | +51.3% | |
| Interest Coverage | 3.82 | 6.04 | -1.31 | 6.11 | 5.65 | 5.26 | 4.54 | 7.02 | 0.87 | 5.33 | -4.99 | -3.82 | 5.47 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into PFE consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PFE stock.
Pfizer Inc.'s current P/E is 18.5x. The average P/E over the last 3 quarters is 11.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pfizer Inc.'s current operating margin is 24.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pfizer Inc.'s business trajectory between earnings reports.